Beta Bionics, Inc. Stock Price, News & Analysis

Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, will release its Q2 2025 financial results on Tuesday, July 29, 2025, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day.

Investors can access the webcast through the company's investor relations website under the "Events & Presentations" section, where it will also be archived for future viewing. For those joining by phone, registration is available through a dedicated link that will provide dial-in details and a personal pin.

[]

Beta Bionics (BBNX) announced plans to integrate its iLet Bionic Pancreas automated insulin delivery system with Abbott's upcoming dual glucose-ketone sensor in the U.S. The iLet system is notable as the first and only automated insulin delivery system making 100% automated dosing decisions, eliminating the need for carb counting or manual insulin calculations. The system currently works with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and this new integration represents an expansion of the existing partnership between the companies. The integration aims to enhance real-time decision-making support for diabetes patients once Abbott's new sensor becomes commercially available.

Beta Bionics (BBNX) reported strong Q1 2025 financial results and raised its annual guidance. Net sales reached $17.6 million, up 36% year-over-year, driven by growth in both DME and PBP channels. The company's installed customer base grew 291% to 19,151 users, with 3,853 new patient starts (48% increase). Despite revenue growth, the company reported increased losses with operating loss of $18.6 million and net loss of $28.7 million. Beta Bionics completed an IPO raising $206 million and secured Prime Therapeutics coverage for its iLet Bionic Pancreas. The company raised its 2025 guidance, now expecting revenue of $82-87 million and PBP channel patient starts of 22-25%. The company maintains $295.5 million in cash and investments.

Beta Bionics (BBNX), a company focused on diabetes management solutions, has announced its participation in the upcoming Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 12:35 PM ET (9:35 AM PT) in Las Vegas. Interested parties can access the live audio webcast through the company's investor relations website under the "Events & Presentations" section at investors.betabionics.com. The presentation recording will be archived on the website for future viewing.

Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, after market close.

The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) on the same day. Investors can access the live call by dialing (888) 596-4144 with passcode 8363701. The webcast will be available in the Investors—Events & Presentations section of the company's website and will be archived for future viewing.

Beta Bionics (Nasdaq: BBNX) has announced an upcoming investor event scheduled for June 22, 2025, in Chicago, coinciding with the 85th Scientific Sessions of the American Diabetes Association. The event will run from 7:00 AM to 8:30 AM Central Time.

The presentation will feature:

• Commercial and financial performance updates
• Demonstration of new patch pump development
• Review of adaptive closed-loop algorithm
• Presentation of new real-world clinical data

The event will be accessible via live webcast through the company's investor relations website. In-person attendance requires registration through Beta Bionics' IR representative. A replay of the webcast and presentation materials will be available on the company website after the event.

Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has appointed Gerard Michel as an independent board director effective March 26, 2025. Michel, currently CEO of Delcath Systems (Nasdaq: DCTH), brings over 30 years of pharmaceutical and medical technology industry experience.

Michel's extensive background includes serving as CFO at Vericel , CFO and VP of Corporate Development at Biodel Inc. (2007-2014), and similar roles at NPS Pharmaceuticals (2002-2007). He previously held positions at Booz Allen and worked in commercial roles at Lederle Labs and Wyeth Labs.

Michel holds an M.S. in Microbiology from the University of Rochester School of Medicine, an M.B.A. from Simon School of Business, and dual B.S. degrees in Biology and Geology.

Beta Bionics (NASDAQ: BBNX) reported strong Q4 and full-year 2024 financial results. Q4 net sales reached $20.4M, up 145% YoY, with DME channel sales of $18.1M (+127%) and PBP channel sales of $2.4M (+491%). The installed customer base grew to 15,298 users (+564%).

Full-year 2024 showed net sales of $65.1M (+443% YoY), with DME channel sales of $58.8M and PBP channel sales of $6.3M. The company completed an IPO raising $206M and launched the Color iLet Bionic Pancreas with FreeStyle Libre 3 Plus integration.

For 2025 guidance, Beta Bionics expects revenue of $80-85M, with over 20% of new patient starts through PBP channel and gross margin of at least 50%. The company ended 2024 with $103.6M in cash and equivalents.

Beta Bionics (NASDAQ: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its Q4 and full year 2024 financial results for March 25, 2025, after market close.

The company will host a conference call and webcast at 4:30 PM ET (1:30 PM PT) on the same day to discuss the financial performance. Investors can access the webcast through the company's investor relations website, and a replay will be available afterward.